



Technology for getting women everywhere tested for early signs of cervical disease

Innocuous, affordable, tissue-health testing screen avoiding the problems of the Pap smear test (unreliable, expensive, underused by too many). Here is how we get there. -

bioZhena Corporation seeks financing with which to manufacture the first batch of our first marketable product within 7 months, the first milestone towards market dominance in scientific family planning and in women's health monitoring.

Prototype already FDA certified. The income from the first product(s) will fund the commercialization of the additional applications of the technology. The project involves electronic monitoring technology developed to make it possible that every pregnancy is deliberate, and to impact on women's healthcare and public health in other ways, too. Note: No charting is involved. This is not a thermometer.

Our personal self-diagnostic device will tell the woman in plain English (or Spanish, Hindi, Chinese, etc.) whether today is one of the three days that she can become pregnant. Three day window, unless stress causes delayed ovulation or suppresses ovulation completely, which is then detected and allowed for, too.

With cervical health tissue screening automatically going on in the background, and with other uses. Apps such as built-in practically instant pregnancy detection; data-based forecast of the EDD, Estimated Date of Delivery; management of PMS/PMDD; management of hormone therapy, to mention a few -- and not to mention fetal sex pre-selection, which our customers will certainly try!

The vision is to get the self-diagnostic supremely user-friendly tool into the hands of every woman, everywhere. Again, note that no charting by the user is involved here; they just read the alphanumeric display (a display in plain language of choice). Thus: SEE DOCTOR when tissue aberration has been detected for several consecutive months – avoiding the disadvantages of the Pap. Triage for colposcopy with biopsy.

The Ovulona™ device generates and makes available to physicians longitudinal data on menstrual cyclic profiles (called folliculogenesis), a new means of patient profiling - from post-adolescence to peri-menopause. Future developments will include optimal method of delivery of therapeutics (minimizing or avoiding side-effects, and fast delivery of medicines) with built-in monitoring of the treatment effects.

Anyone interested in looking at the investment opportunity, please get in touch. For more particulars, review the information referenced below.

Vaclav Kirsner, PhD

Founder CEO, bioZhena Corporation

http://www.linkedin.com/profile/view?id=3526343&authType=name&authToken=7Eli&locale=en_US&pvs=pp&trk=ppro viewmore

<http://biozhena.wordpress.com/about>

Email: vaclavkirsner@yahoo.com

bioZhena Corporation

2908 Killarney Drive, Laporte, Colorado 80535, USA

Vaclav Kirsner, Ph.D., Chairman and CEO

vaclavkirsner@yahoo.com

970-484-1272